Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 530 articles:
HTML format



Single Articles


    May 2020
  1. CONNOLEY D, Francis-Graham S, Storer M, Ekeke N, et al
    Detection, stratification, and treatment of hepatitis C positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
    J Viral Hepat. 2020 May 25. doi: 10.1111/jvh.13336.
    PubMed     Abstract available


  2. DE LEDINGHEN V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, et al
    Sofosbuvir-based regimens are suboptimal in patients with genotype 2 chronic hepatitis C infection: Real-life experience from the HEPATHER ANRS CO22 cohort.
    J Viral Hepat. 2020 May 21. doi: 10.1111/jvh.13321.
    PubMed     Abstract available


  3. DIETZ J, Kalinina OV, Vermehren J, Peiffer KH, et al
    Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322.
    PubMed     Abstract available


  4. YE W, Li X
    Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13323.
    PubMed     Abstract available


  5. KIM NG, Kullar R, Khalil H, Saab S, et al
    Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics.
    J Viral Hepat. 2020 May 9. doi: 10.1111/jvh.13317.
    PubMed     Abstract available


  6. LI MR, Xu ZG, Lu JH, Zheng HW, et al
    Clinical Features of Hepatitis B Patients at Immune-tolerance Phase with Basal Core Promoter and/or Precore Mutations.
    J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13315.
    PubMed     Abstract available


  7. NING G, Zhen LM, Xu WX, Li XJ, et al
    Suppression of complement component2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients.
    J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13319.
    PubMed     Abstract available


  8. YUEN L, Revill PA, Rosenberg G, Wagner J, et al
    HBV variants are common in the "immune-tolerant"phase of chronic hepatitis B.
    J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13318.
    PubMed     Abstract available


  9. LIM TS, Lee HW, Lee JI, Kim IH, et al
    Predictive score for hepatocellular carcinoma after hepatitis B eantigen loss in patients treated with entecavir or tenofovir.
    J Viral Hepat. 2020 May 7. doi: 10.1111/jvh.13316.
    PubMed     Abstract available


  10. JEON MY, Lee JS, Lee HW, Kim BK, et al
    Entecavirandtenofoviron renal function in patients with hepatitis B virus related hepatocellular carcinoma.
    J Viral Hepat. 2020 May 4. doi: 10.1111/jvh.13313.
    PubMed     Abstract available


  11. LEE WM, King WC, Schwarz KB, Rule J, et al
    Prevalence and Clinical Features of Patients with Concurrent HBsAg and Anti-HBs: Evaluation of the Hepatitis B Research Network Cohort.
    J Viral Hepat. 2020 May 4. doi: 10.1111/jvh.13312.
    PubMed     Abstract available


  12. PAN YC, Jia ZF, Wang YQ, Yang N, et al
    The role of cesarean section and non-breastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg and HBeAg positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2020 May 3. doi: 10.1111/jvh.13314.
    PubMed     Abstract available


  13. ZHANG M, O'Keefe D, Iwamoto M, Sann K, et al
    High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    J Viral Hepat. 2020 May 2. doi: 10.1111/jvh.13311.
    PubMed     Abstract available


    April 2020
  14. CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
    Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
    PubMed     Abstract available


  15. CHIU WN, Hung CH, Lu SN, Chen MY, et al
    Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
    J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
    PubMed     Abstract available


  16. HONG CY, Sinn DH, Kang D, Paik SW, et al
    Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
    PubMed     Abstract available


  17. YIP TC, Wong VW, Chan HL, Tse YK, et al
    Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13307.
    PubMed     Abstract available


  18. STROFFOLINI T, Ciancio A, Furlan C, Vinci M, et al
    Migratory flow and hepatitis Delta infection in Italy: a new challenge at the beginning of the third millennium.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13310.
    PubMed     Abstract available


  19. CHO JY, Sohn W, Paik YH, Gwak GY, et al
    Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients - functional cure unlikely.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13306.
    PubMed     Abstract available


  20. WANG H, Wang M, Huang J, Xu R, et al
    Novel hepatitis B virus surface antigen mutations associated with occult genotype Bhepatitis B virus infection affect HBsAgdetection.
    J Viral Hepat. 2020 Apr 26. doi: 10.1111/jvh.13309.
    PubMed     Abstract available


  21. LEE J, Park JY, Yang SJ, Lee JY, et al
    Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
    J Viral Hepat. 2020 Apr 17. doi: 10.1111/jvh.13291.
    PubMed     Abstract available


  22. LI YR, Chen WC, Tsai WL, Cheng JS, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without anti-viral prophylaxis.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13302.
    PubMed     Abstract available


  23. AMOUGOU-ATSAMA M, Atangana PJA, Noah Noah D, Fewou Moundipa P, et al
    The role of hepatitis C virus genotypes and core mutations inhepatocellular carcinomain Cameroon.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13303.
    PubMed     Abstract available


  24. HUANG X, Young KH, Guo W, Wang Y, et al
    Identification of Hepatitis B virus etiologic antigens, HBx and Pre-S2, in Diffuse Large B-cell Lymphoma.
    J Viral Hepat. 2020 Apr 13. doi: 10.1111/jvh.13301.
    PubMed     Abstract available


  25. ABU FREHA N, Wainstock T, Poupko L, Shemer Avni Y, et al
    Maternal hepatitis B or hepatitis C virus carrier s tatus and long-term infectious morbidity of the offspring: A population-based cohort study.
    J Viral Hepat. 2020 Apr 9. doi: 10.1111/jvh.13300.
    PubMed     Abstract available


  26. DESAI M, White E, Vora N, Gilson R, et al
    High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxis.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13297.
    PubMed     Abstract available


  27. TSENG CW, Wu SF, Chen CY, Ho YC, et al
    Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
    PubMed     Abstract available


    March 2020
  28. BEYAN C, Beyan E
    Plateletcrit may not be an index for predicting liver fibrosis in patients with chronic hepatitis B.
    J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13289.
    PubMed     Abstract available


  29. HUANG R, Wang J, Xia J, Wu C, et al
    Reply to the letter by Beyan et al "Plateletcrit may not be an index for predicting of liver fibrosis in patients with chronic hepatitis B".
    J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13288.
    PubMed     Abstract available


  30. SPREAFICO M, Raffaele L, Guarnori I, Foglieni B, et al
    Prevalence and 9-year incidence of hepatitis E virus infection among north italian blood donors: Estimated transfusion risk.
    J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13296.
    PubMed     Abstract available


  31. CHEN YP, Huang LW, Lin XY, Hu XM, et al
    Alanine Aminotransferase Influencing Performances of Routine Available Tests Detecting Hepatitis B Related Cirrhosis.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13293.
    PubMed     Abstract available


  32. VAN SANTEN DK, Sacks-Davis R, Doyle JS, Scott N, et al
    Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294.
    PubMed     Abstract available


  33. JANJUA NZ, Wong S, Darvishian M, Butt ZA, et al
    The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295.
    PubMed     Abstract available


  34. MEYER M, Bondy L, Koivu S, Koval J, et al
    New Hepatitis C Diagnoses in Ontario, Canada are associated with the Local Prescription Patterns of a Controlled Release Opioid.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292.
    PubMed     Abstract available


  35. FONSECA MA, Ling Zhi Jie J, Al-Siyabi O, Co-Tanko V, et al
    The efficacy of hepatitis B treatments in achieving HBsAgseroclearance: a systematic review and meta-analysis.
    J Viral Hepat. 2020 Mar 14. doi: 10.1111/jvh.13283.
    PubMed     Abstract available


  36. BRADSHAW D, Vasylyeva TI, Davis C, Pybus OG, et al
    Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England.
    J Viral Hepat. 2020 Mar 1. doi: 10.1111/jvh.13286.
    PubMed     Abstract available


    February 2020
  37. RIVEIRO-BARCIELA M, Rando-Segura A, Barreira-Diaz A, Bes M, et al
    Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?
    J Viral Hepat. 2020 Feb 27. doi: 10.1111/jvh.13285.
    PubMed     Abstract available


  38. BIELEN R, Koc OM, Busschots D, Verrando R, et al
    Validation of hepatitis C virus RNA detection using capillary blood by fingerprick (GenXpert system)- Hepatitis C fingerprick study.
    J Viral Hepat. 2020 Feb 27. doi: 10.1111/jvh.13284.
    PubMed     Abstract available


  39. DENG Y, Campbell F, Han K, Theodore D, et al
    Randomized Clinical Trials Towards a Single-Visit Cure for Chronic Hepatitis C: Oral GSK2878175 and Injectable RG-101 in Chronic Hepatitis C Patients and Long-Acting Injectable GSK2878175 in Healthy Participants.
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13282.
    PubMed     Abstract available


  40. KNOP V, Mauss S, Goeser T, Geier A, et al
    Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C (HCV) infection receiving direct acting antiviral therapy- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280.
    PubMed     Abstract available


  41. MIRANDA AC, Mendez J, Serrao R, Vale F, et al
    Chronic hepatitis C treatment in HIV Co-infection in Portugal: Results from a cohort of 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13281.
    PubMed     Abstract available


  42. KIM J, Chung SJ, Sinn DH, Lee KW, et al
    Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients.
    J Viral Hepat. 2020 Feb 14. doi: 10.1111/jvh.13279.
    PubMed     Abstract available


  43. MOJSIEJCZUK L, Torres C, Flichman D, Campos RH, et al
    Long-term evolution of hepatitis B virus genotype F: strong association between viral diversification and the prehistoric settlement of Central and South America.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13273.
    PubMed     Abstract available


  44. VAN CAMPENHOUT MJH, van Bommel F, Pfefferkorn M, Fischer J, et al
    Serum hepatitis B virus rna predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13272.
    PubMed     Abstract available


  45. SHIHA G, Mousa N, Soliman R, Mikhail NN, et al
    Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13276.
    PubMed     Abstract available


  46. LIU Z, Mao X, Yu K, Suo C, et al
    Prevalence of HCV Resistance-Associated Substitutions amongTreatment FailurePatients receiving Direct-Acting Antiviral Agents.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13270.
    PubMed     Abstract available


  47. CIMINI E, Sacchi A, Grassi G, Casetti R, et al
    Persistent gamma delta T-cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy induced cure.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13277.
    PubMed     Abstract available


  48. HIGASHI RT, Jain MK, Quirk L, Rich NE, et al
    Patient and Provider-Level Barriers to Hepatitis C Screening and Linkage to Care: A Mixed-Methods Evaluation.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13278.
    PubMed     Abstract available


  49. TAO YC, Wang ML, Zhang DM, Wu DB, et al
    Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13275.
    PubMed     Abstract available


  50. FALADE-NWULIA O, Ward KM, McCormick S, Mehta SH, et al
    Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274.
    PubMed     Abstract available


    January 2020
  51. SHIHA G, Soliman R, Serwah A, Mikhail NN, et al
    A same day "test and treat" model for chronic HCV and HBV infection: Results from two community-based pilot studies in Egypt.
    J Viral Hepat. 2020 Jan 30. doi: 10.1111/jvh.13268.
    PubMed     Abstract available


  52. MD SAID R, Mohd Zain R, Chan HK, Soelar SA, et al
    Find the Missing Millions: Malaysia's Experience with Nationwide Hepatitis C Screening Campaign in the General Population.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13267.
    PubMed     Abstract available


  53. CAVEN M, Robinson EM, Eriksen AJ, Fletcher EH, et al
    Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269.
    PubMed     Abstract available


  54. GOEL A, Padmaprakash KV, Benjamin M, Katiyar H, et al
    Temporal profile of HEV RNA concentration in blood and stool from patients with acute uncomplicated hepatitis E in a region with genotype 1 predominance.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13266.
    PubMed     Abstract available


  55. WANG J, Xia J, Yan X, Yang Y, et al
    Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B.
    J Viral Hepat. 2020 Jan 25. doi: 10.1111/jvh.13264.
    PubMed     Abstract available


  56. LIU CH, Yang SS, Peng CY, Lin WT, et al
    Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    J Viral Hepat. 2020 Jan 25. doi: 10.1111/jvh.13265.
    PubMed     Abstract available


  57. TRAN TH, Nguyen BT, Nguyen TA, Pham TTP, et al
    Dried blood spots perform well to identify patients with active HCV infection in Vietnam.
    J Viral Hepat. 2020 Jan 24. doi: 10.1111/jvh.13263.
    PubMed     Abstract available


  58. POURMARZI D, Smirnov A, Hall L, Thompson H, et al
    Enablers and barriers for the provision of community-based HCV treatment: a case study of a real-world practice.
    J Viral Hepat. 2020 Jan 20. doi: 10.1111/jvh.13259.
    PubMed     Abstract available


  59. OU Q, Guo J, Zeng Y, Chen H, et al
    Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection.
    J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13260.
    PubMed     Abstract available


  60. POORDAD F, Castro RE, Asatryan A, Aguilar H, et al
    Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +/- Ribavirin in the TOPAZ-I and TOPAZ-II Trials.
    J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261.
    PubMed     Abstract available


  61. TRAM J, Le Baccon-Sollier P, Bollore K, Ducos J, et al
    RNA testing for the diagnosis of acute hepatitis A during the 2017 outbreak in France.
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13255.
    PubMed     Abstract available


  62. YAMAMICHI S, Miuma S, Wada T, Masumoto H, et al
    Deep sequence analysis of NS5A resistance-associated substitution changes in patients reinfected with the hepatitis C virus after liver transplantation.
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13256.
    PubMed     Abstract available


  63. FEDORCHENKO SV, Martynovych T, Klimenko Z, Yanchenko V, et al
    Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/ paritaprevir/ ritonavir, dasabuvir + sofosbuvir + r
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13254.
    PubMed     Abstract available


    December 2019
  64. CHIEN RN, Liaw YF
    Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics.
    J Viral Hepat. 2019 Dec 23. doi: 10.1111/jvh.13253.
    PubMed     Abstract available


  65. XIAO Y, Howell J, van Gemert C, Thompson AJ, et al
    Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model.
    J Viral Hepat. 2019 Dec 19. doi: 10.1111/jvh.13252.
    PubMed     Abstract available


  66. IRVIN R, Chander G, Ward KM, Manogue S, et al
    Unreported Alcohol Use Was Common But Did Not Impact Hepatitis C Cure in HIV-Infected Persons Who Use Drugs.
    J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251.
    PubMed     Abstract available


  67. WONG L, Cheung TH, Yim SF, Lao TT, et al
    Prevalence and Impact of Hepatitis B Virus Infection in Ovarian Cancer Patients in an Endemic Area - a Retrospective Cohort Study.
    J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13250.
    PubMed     Abstract available


  68. IM JH, Woo HT, Ha B, Jung J, et al
    Effectiveness of Single-Dose Administration of Inactivated Hepatitis A Virus Vaccination in the Republic of Korea Armed Forces, 2013-2016.
    J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13249.
    PubMed     Abstract available


  69. FONTANA RJ, Avigan MI, Janssen HLA, Regev A, et al
    Liver safety assessment in clinical trials of new agents for chronic hepatitis B.
    J Viral Hepat. 2019 Dec 11. doi: 10.1111/jvh.13223.
    PubMed     Abstract available


  70. SONDERUP M, Dusheiko G, Desalegn H, Lemoine M, et al
    Hepatitis B in sub-Saharan Africa - how many patients need therapy?
    J Viral Hepat. 2019 Dec 4. doi: 10.1111/jvh.13247.
    PubMed     Abstract available


  71. UDOMPAP P, Sukonrut K, Suvannarerg V, Pongpaibul A, et al
    Prospective Comparison of Transient Elastography, Point Shear Wave Elastography, APRI, and FIB-4 for Staging Liver Fibrosis in Chronic Viral Hepatitis.
    J Viral Hepat. 2019 Dec 4. doi: 10.1111/jvh.13246.
    PubMed     Abstract available


    November 2019
  72. GANE EJ, Charlton MR, Mohamed R, Sollano JD, et al
    Asian Consensus Recommendations on Optimizing the Diagnosis and Initiation of Treatment of Hepatitis B Virus Infection in Resource-Limited Settings.
    J Viral Hepat. 2019 Nov 30. doi: 10.1111/jvh.13244.
    PubMed     Abstract available


  73. SULLIVAN RP, Davies J, Binks P, Dhurrkay RG, et al
    Point of care and oral fluid Hepatitis B testing in remote Indigenous communities of northern Australia.
    J Viral Hepat. 2019 Nov 29. doi: 10.1111/jvh.13243.
    PubMed     Abstract available


  74. PAN XB, Yu J, Li HJ, Wu N, et al
    Young Chinese children without seroprotective hepatitis B surface antibody could be at risk of hepatitis B virus infection through horizontal transmission.
    J Viral Hepat. 2019 Nov 29. doi: 10.1111/jvh.13242.
    PubMed     Abstract available


  75. BOYLE A, Marra F, Peters E, Datta S, et al
    Eight weeks of Sofosbuvir/Velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
    J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239.
    PubMed     Abstract available


  76. CRESPO J, Cuadrado A, Perello C, Cabezas J, et al
    Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: data for designing a cost-effective elimination policy in Spain.
    J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13238.
    PubMed     Abstract available


  77. STARBIRD LE, Budhathoki C, Han HR, Sulkowski MS, et al
    Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial.
    J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13241.
    PubMed     Abstract available


  78. BHANDARI R, Morey S, Hamoodi A, Thompson C, et al
    High rate of hepatitis C re-infection following antiviral treatment in the North East England Prisons.
    J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13240.
    PubMed     Abstract available


  79. DA BL, Surana P, Takyar V, Kleiner DE, et al
    Vibration-Controlled Transient Elastography for the Detection of Cirrhosis in Chronic Hepatitis D Infection.
    J Viral Hepat. 2019 Nov 19. doi: 10.1111/jvh.13235.
    PubMed     Abstract available


  80. SUNG JC, Bosh C, Wyatt B, Miller M, et al
    Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center.
    J Viral Hepat. 2019 Nov 19. doi: 10.1111/jvh.13234.
    PubMed     Abstract available


  81. BAJIS S, Grebely J, Hajarizadeh B, Applegate T, et al
    Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233.
    PubMed     Abstract available


  82. NAYAGAM S, Shimakawa Y, Lemoine M
    Mother to child transmission of hepatitis B: What more needs to be done to eliminate it around the world?
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13231.
    PubMed     Abstract available


  83. CACCIOLA I, Borgia F, Filomia R, Pitrone C, et al
    Outcome of cutaneous psoriasis in hepatitis C virus infected patients treated with Direct Acting Antiviral therapy.
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13230.
    PubMed     Abstract available


  84. MCDONALD SA, Pollock KG, Barclay ST, Goldberg DJ, et al
    Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    J Viral Hepat. 2019 Nov 6. doi: 10.1111/jvh.13232.
    PubMed     Abstract available


    October 2019
  85. CARDOZO EF, Ji D, Lau G, Schinazi RF, et al
    Disentangling the life-spans of hepatitis C virus infected cells and intracellular vRNA replication-complexes during direct acting antiviral therapy.
    J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13229.
    PubMed     Abstract available


  86. LUO H, Tan N, Kang Q, Pan J, et al
    HBV pgRNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues.
    J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13227.
    PubMed     Abstract available


  87. SAHAKYAN Y, Wong W, Yi Q, Thein HH, et al
    Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: over 15 years of follow-up.
    J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13226.
    PubMed     Abstract available


  88. CARRAT F, Nahon P, Fontaine H, Pol S, et al
    Comparing Interferon-free with Interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox.
    J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13225.
    PubMed     Abstract available


  89. MARTIN P, Jadoul M, Pol S
    HCV in the Hemodialysis Population: treat now or later?
    J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224.
    PubMed     Abstract available


  90. LIM TS, Lee JS, Kim BK, Lee HW, et al
    An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate.
    J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13222.
    PubMed     Abstract available


  91. BAIK D, Kim BW, Oh JK, Kim KA, et al
    Costs of Viral Hepatitis B in the Republic of Korea, 2002-2015.
    J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13219.
    PubMed     Abstract available


  92. YANES-LANE M, Dussault C, Linthwaite B, Cox J, et al
    Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review.
    J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13220.
    PubMed     Abstract available


  93. LYU J, Wang S, He Q, Pan C, et al
    Hep B Moms: A cross-sectional study of mother-to-child transmission risk among pregnant Asian American women with chronic hepatitis B in New York City, 2007-2017.
    J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13221.
    PubMed     Abstract available


  94. ZENG Y, Chen S, Fu Y, Wu W, et al
    Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13216.
    PubMed     Abstract available


  95. DANIEL KE, Saeian K, Rizvi S
    Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
    J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218.
    PubMed     Abstract available


  96. RUSSO FP, Zanetto A, Gambato M, Bortoluzzi I, et al
    Hepatitis C virus eradication with direct acting antiviral improves insulin resistance.
    J Viral Hepat. 2019 Oct 9. doi: 10.1111/jvh.13215.
    PubMed     Abstract available


    September 2019
  97. YANG R, Gui X, Ke H, Xiong Y, et al
    Long-term observation on Hepatitis B surface antigen (HBsAg) seroclearance in therapy experienced HIV/HBV co-infected Chinese.
    J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13212.
    PubMed     Abstract available


  98. SHEN K, Yang NS, Huang W, Fitzpatrick TS, et al
    A crowdsourced intervention to decrease hepatitis B stigma in men who have sex with men in China: a cohort study.
    J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13213.
    PubMed     Abstract available


  99. PHILLIPS C, Schulkind J, O'Sullivan M, Edelman N, et al
    Improving access to care for People Who Inject Drugs: Qualitative evaluation of Project ITTREAT, an integrated community hepatitis C service.
    J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13214.
    PubMed     Abstract available


  100. PAPATHEODORIDI M, Hadziyannis E, Berby F, Zachou K, et al
    Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019 Sep 28. doi: 10.1111/jvh.13211.
    PubMed     Abstract available


  101. BAKAROZI M, Mavropoulos A, Bogdanos DP, Dalekos GN, et al
    Title: p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13209.
    PubMed     Abstract available


  102. RAO H, Song G, Li G, Yang Y, et al
    Safety and efficacy of coblopasvir and sofosbuvir in patients with genotype 1, 2, 3, and 6 HCV infections without or with compensated cirrhosis.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13208.
    PubMed     Abstract available


  103. BUCHANAN R, Cooper K, Grellier L, Khakoo SI, et al
    The testing of people with any risk factor for Hepatitis C in community pharmacies is cost effective.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13207.
    PubMed     Abstract available


  104. VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
    Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
    PubMed     Abstract available


  105. MAK JSM, Lao TT, Leung MBW, Chung CHS, et al
    Ovarian HBV replication following ovulation induction in female Hepatitis B carriers undergoing IVF treatment: a prospective observational study.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13210.
    PubMed     Abstract available


  106. SAINZ T, Fernandez McPhee C, Dominguez-Rodriguez S, Hierro L, et al
    Longitudinal Evolution Of Vertically HIV/HCV Coinfected Vs HCV Monoinfected Children.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13206.
    PubMed     Abstract available


  107. MILLER LS, Millman AJ, Lom J, Osinubi A, et al
    Defining the Hepatitis C Cure Cascade in an Urban Health System Using the Electronic Health Record.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199.
    PubMed     Abstract available


  108. CHO KS, Sohn W, Lee YC, Chi SA, et al
    Use of cyclooygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nested case-control study using a nationwide population-based data.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13201.
    PubMed     Abstract available


  109. IRELAND G, Simmons R, Hickman M, Harris R, et al
    Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13203.
    PubMed     Abstract available


  110. ARSLAN F
    Cytomegalovirus and hepatitis after bone marrow transplantation.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13200.
    PubMed     Abstract available


  111. LAURSEN TL, Siggaard CB, Kazankov K, Sandahl TD, et al
    Time-dependent improvement of liver inflammation, fibrosis, and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13204.
    PubMed     Abstract available


  112. HE WQ, Duong MC, Gidding H, MacLachlan J, et al
    Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016.
    J Viral Hepat. 2019 Sep 9. doi: 10.1111/jvh.13202.
    PubMed     Abstract available


    August 2019
  113. CATLETT B, Lamoury FMJ, Bajis S, Hajarizadeh B, et al
    Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.
    J Viral Hepat. 2019 Aug 26. doi: 10.1111/jvh.13196.
    PubMed     Abstract available


  114. LIMOTHAI U, Chuaypen N, Poovorawan K, Chotiyaputta W, et al
    Baseline and kinetics of serum HBV RNA predict response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019 Aug 25. doi: 10.1111/jvh.13195.
    PubMed     Abstract available


  115. JACKA B, Roy E, Hoj S, Minoyan N, et al
    Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13194.
    PubMed     Abstract available


  116. ROSA-HEZODE I, Chousterman M, Costes L, Labourdette C, et al
    Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening program: the PRECAVIR study.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13192.
    PubMed     Abstract available


  117. TSAI MC, Lin CY, Hung CH, Lu SN, et al
    Evolution of Renal function under directly acting antivirals treatment for chronic hepatitis C: A real world experience.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13193.
    PubMed     Abstract available


  118. TO WP, Mak LY, Wong DK, Fung J, et al
    Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
    J Viral Hepat. 2019 Aug 16. doi: 10.1111/jvh.13191.
    PubMed     Abstract available


  119. FUJII H, Enomoto M, Murakami Y, Hagihara A, et al
    Last crusade against HCV: Direct-acting antiviral treatment for marginalized populations.
    J Viral Hepat. 2019 Aug 14. doi: 10.1111/jvh.13190.
    PubMed     Abstract available


  120. YIN X
    It is too early to evaluate mother-to-child transmission of hepatitis B within 24 hours after delivery.
    J Viral Hepat. 2019 Aug 14. doi: 10.1111/jvh.13189.
    PubMed     Abstract available


  121. TRICKEY A, Fraser H, Lim AG, Walker JG, et al
    Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional, and country levels: a modelling study.
    J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187.
    PubMed     Abstract available


  122. KRAMER J, Wolffram I, Fruh U, Batz O, et al
    Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany.
    J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13188.
    PubMed     Abstract available


  123. LUSIVIKA-NZINGA C, Fontaine H, Dorival C, Simony M, et al
    The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13186.
    PubMed     Abstract available


    July 2019
  124. SINN DH, Kim SE, Kim BK, Kim JH, et al
    The Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Virus Infected Patients Outside Current Treatment Criteria.
    J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13185.
    PubMed     Abstract available


  125. MASON LMK, Veldhuijzen IK, Duffell E, van Ahee A, et al
    Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: a systematic review.
    J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13182.
    PubMed     Abstract available


  126. MAISA A, Semple S, Griffiths A, Ngui SL, et al
    Risk behaviours of homeless people who inject drugs during an outbreak of hepatitis C, Northern Ireland, 2016-2017.
    J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13184.
    PubMed     Abstract available


  127. MARRONE A, Ciotti M, Rinaldi L, Adinolfi LE, et al
    Hepatitis B and C virus infection and risk of hematological malignancies.
    J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13183.
    PubMed     Abstract available


  128. WINETSKY D, Zucker J, Carnevale C, Theodore D, et al
    Attitudes, practices and perceived barriers to hepatitis C screening among medical residents at a large urban academic medical center.
    J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13181.
    PubMed     Abstract available


  129. USMAN Z, Mijocevic H, Karimzadeh H, Daumer M, et al
    Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg positive chronic HBV infection.
    J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13180.
    PubMed     Abstract available


  130. SCHAUER C, van Rijnsoever M, Gane E
    Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
    J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13179.
    PubMed     Abstract available


  131. GOUNTAS I, Sypsa V, Papatheodoridis G, Paraskevis D, et al
    A Hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece. Insights from a mathematical modeling study.
    J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13178.
    PubMed     Abstract available


  132. MAXIME G, Mouna L, Coustilleres F, Lemee V, et al
    Invasive meningoencephalitis as the first manifestation of hepatitis A.
    J Viral Hepat. 2019 Jul 18. doi: 10.1111/jvh.13177.
    PubMed     Abstract available


  133. MCDONALD GB, Sarmiento JI, Rees-Lui G, Myerson D, et al
    Cytomegalovirus hepatitis after bone marrow transplantation: An autopsy study with clinical, histologic, and laboratory correlates.
    J Viral Hepat. 2019 Jul 17. doi: 10.1111/jvh.13176.
    PubMed     Abstract available


  134. READ P, Gilliver R, Kearley J, Lothian R, et al
    Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting Antiviral Therapy for Hepatitis C Infection.
    J Viral Hepat. 2019 Jul 12. doi: 10.1111/jvh.13175.
    PubMed     Abstract available


  135. WU J, Guo N, Zhang X, Xiong C, et al
    HEV-LFS : a novel scoring model for patients with hepatitis E virus-related liver failure.
    J Viral Hepat. 2019 Jul 11. doi: 10.1111/jvh.13174.
    PubMed     Abstract available


  136. DESHPANDE R, Stepanova M, Golabi P, Brown K, et al
    Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Hemodialysis units.
    J Viral Hepat. 2019 Jul 11. doi: 10.1111/jvh.13173.
    PubMed     Abstract available


  137. IKEDA H, Watanabe T, Atsukawa M, Toyoda H, et al
    Evaluation of 8-Week Glecaprevir/Pibrentasvir Treatment in Direct-acting Antiviral -naive Non-cirrhotic Genotype 1 and 2 HCV Patients in a Real-world Setting in Japan.
    J Viral Hepat. 2019 Jul 6. doi: 10.1111/jvh.13170.
    PubMed     Abstract available


  138. PRONIER C, Fontaine H, Dorival C, Carrat F, et al
    Genetic diversity of genotype 6 HCV infections in France: epidemiology and consequences for treatment strategy.
    J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13171.
    PubMed     Abstract available


  139. MENDIZABAL M, Ridruejo E, Ceballos S, Sixto M, et al
    The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina.
    J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13172.
    PubMed     Abstract available


  140. XIE Y, Yi W, Zhang L, Lu Y, et al
    Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels.
    J Viral Hepat. 2019;26 Suppl 1:42-49.
    PubMed     Abstract available


  141. LI G, Zhang Q, Yu Y, Qiu C, et al
    Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment.
    J Viral Hepat. 2019;26 Suppl 1:50-58.
    PubMed     Abstract available


  142. DUAN BW, Tian LT, Lin DD, Zhang J, et al
    Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection.
    J Viral Hepat. 2019;26 Suppl 1:85-89.
    PubMed     Abstract available


  143. ZHANG Q, Li G, Yu Y, Qiu C, et al
    Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naive chronic hepatitis B patients.
    J Viral Hepat. 2019;26 Suppl 1:59-68.
    PubMed     Abstract available


  144. REN H
    On the way towards the eradication of chronic hepatitis B.
    J Viral Hepat. 2019;26 Suppl 1:3-4.
    PubMed    


  145. FAN H, Lin L, Jia S, Xie M, et al
    Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B.
    J Viral Hepat. 2019;26 Suppl 1:77-84.
    PubMed     Abstract available


  146. LIU Y, Li H, Yan X, Wei J, et al
    Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.
    J Viral Hepat. 2019;26 Suppl 1:69-76.
    PubMed     Abstract available


  147. REN H, Huang Y
    Effects of pegylated interferon-alpha based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.
    J Viral Hepat. 2019;26 Suppl 1:5-31.
    PubMed     Abstract available


  148. CHEN H, Luo S, Lu W, Chen Z, et al
    Serum protein expression patterns in detecting a new viral protein in HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019;26 Suppl 1:90-97.
    PubMed     Abstract available


  149. LI MH, Yi W, Zhang L, Lu Y, et al
    Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
    J Viral Hepat. 2019;26 Suppl 1:32-41.
    PubMed     Abstract available


    June 2019
  150. PELEG N, Issachar A, Sneh-Arbib O, Cohen-Naftaly M, et al
    Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virologic response.
    J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13167.
    PubMed     Abstract available


  151. CHUNG S, Roh EY, Park B, Lee Y, et al
    GWAS identifying HLA-DPB1 gene variants associated with responsiveness to hepatitis B virus vaccination in Koreans: Independent association of HLA-DPB1*04:02 possessing rs1042169 G - rs9277355 C - rs9277356 A.
    J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13168.
    PubMed     Abstract available


  152. VILLANI R, Monami M, Di Cosimo F, Fioravanti G, et al
    Direct-Acting antivirals for HCV treatment in older patients: a systematic review and meta-analysis.
    J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13169.
    PubMed     Abstract available


  153. ASSELAH T, Shafran SD, Bourgeois S, Lai CL, et al
    Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4, and 6 infection.
    J Viral Hepat. 2019 Jun 19. doi: 10.1111/jvh.13159.
    PubMed     Abstract available


  154. LU M, Wu KH, Li J, Moorman AC, et al
    Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13162.
    PubMed     Abstract available


  155. RAGONNET-CRONIN M, Hostager R, Hedskog C, Osinusi A, et al
    HIV co-infection is associated with increased transmission risk in patients with chronic hepatitis C virus.
    J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13160.
    PubMed     Abstract available


  156. VERCOUTER AS, Van Houtte F, Verhoye L, Gonzalez Fraile I, et al
    Hepatitis E virus prevalence in Flemish blood donors.
    J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13161.
    PubMed     Abstract available


  157. LIU J, Wang J, Yan T, Du D, et al
    Efficacy and safety of Telbivudine and Tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: a real-life practice.
    J Viral Hepat. 2019 Jun 8. doi: 10.1111/jvh.13156.
    PubMed     Abstract available


  158. DEGASPERI E, Galmozzi E, Facchetti F, Farina E, et al
    TLL1 Variants do not predict hepatocellular carcinoma development in hcv cirrhotic patients treated with direct-acting antivirals.
    J Viral Hepat. 2019 Jun 8. doi: 10.1111/jvh.13155.
    PubMed     Abstract available


    May 2019
  159. RIDRUEJO E, Cheinquer H, Marciano S, Mendizabal M, et al
    B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
    J Viral Hepat. 2019 May 29. doi: 10.1111/jvh.13148.
    PubMed     Abstract available


  160. WILLEMSE S, Smit C, Sogni P, Sarcletti M, et al
    Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV-patients with cirrhosis.
    J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13146.
    PubMed     Abstract available


  161. VAN CAMPENHOUT MJH, Rijckborst V, Brouwer WP, van Oord GW, et al
    Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13117.
    PubMed     Abstract available


  162. CLARKE WT, Miranda J, Neidich E, Hudock R, et al
    Metabolic Syndrome and Liver Steatosis occur at lower body mass index in US Asian patients with Chronic Hepatitis B.
    J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13147.
    PubMed     Abstract available


  163. NANGIA G, Borges K, Reddy KR
    Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option.
    J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13130.
    PubMed     Abstract available


  164. LAWITZ E, Gane E, Feld JJ, Buti M, et al
    Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.
    J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13132.
    PubMed     Abstract available


  165. ATSAMA MA, Marchio A, Bivigou-Mboumba B, Noah Noah D, et al
    Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon.
    J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13131.
    PubMed     Abstract available


  166. HLAING NKT, Nangia G, Tun KT, Lin S, et al
    High Sustained Virologic Response in Genotypes 3 and 6 with Generic NS5A Inhibitor and Sofosbuvir regimens in chronic HCV in Myanmar.
    J Viral Hepat. 2019 May 18. doi: 10.1111/jvh.13133.
    PubMed     Abstract available


  167. LHOMME S, Gallian P, Dimeglio C, Assal A, et al
    Viral load and clinical manifestations of hepatitis E virus genotype 3 infections.
    J Viral Hepat. 2019 May 16. doi: 10.1111/jvh.13128.
    PubMed     Abstract available


  168. BERGLOV A, Hallager S, Weis N
    Hepatitis E during pregnancy: maternal and fetal case-fatality rates and adverse outcomes - a systematic review.
    J Viral Hepat. 2019 May 16. doi: 10.1111/jvh.13129.
    PubMed     Abstract available


  169. ZHAO M, Zou H, Chen Y, Zheng S, et al
    Efficacy of antepartum administration of Hepatitis B immunoglobulin in preventing mother-to-child transmission of Hepatitis B virus.
    J Viral Hepat. 2019 May 14. doi: 10.1111/jvh.13123.
    PubMed     Abstract available


  170. VAN DAMME P, Dionne M, Leroux-Roels G, Van Der Meeren O, et al
    Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.
    J Viral Hepat. 2019 May 14. doi: 10.1111/jvh.13125.
    PubMed     Abstract available


  171. MOORE MS, Greene SK, Bocour A, Brown CM, et al
    Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates.
    J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124.
    PubMed     Abstract available


  172. NING Q, Wu D, Wang G, Ren H, et al
    Roadmap to Functional Cure of Chronic Hepatitis B: an expert consensus.
    J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13126.
    PubMed     Abstract available


  173. MORALES-ARRAEZ D, Alonso-Larruga A, Diaz-Flores F, Garcia Dopico JA, et al
    Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert.
    J Viral Hepat. 2019 May 11. doi: 10.1111/jvh.13122.
    PubMed     Abstract available


  174. GHOSH A, Mondal RK, Romani S, Bagchi S, et al
    Persistent Gamma Delta-T cell Dysfunction in Chronic HCV Infection Despite Direct Acting Antiviral Therapy Induced Cure.
    J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13121.
    PubMed     Abstract available


  175. LITWIN AH, Drolet M, Nwankwo C, Torrens M, et al
    Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.
    J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13119.
    PubMed     Abstract available


  176. LIU W, Liang H, Wang S, Wu C, et al
    Transcriptional response of USP18 predicts treatment outcomes of interferon-alpha in HBeAg-positive chronic hepatitis B patients.
    J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13120.
    PubMed     Abstract available


  177. JENG WJ, Yang HI
    Discrepant range of sPD-1 in different studies of Chronic hepatitis B.
    J Viral Hepat. 2019 May 4. doi: 10.1111/jvh.13102.
    PubMed     Abstract available


  178. ZHOU L, Li X, Huang X, Chen L, et al
    Reply to the letter by Jeng et al. 'Discrepant range of sPD-1 in different studies of Chronic hepatitis B'.
    J Viral Hepat. 2019 May 4. doi: 10.1111/jvh.13118.
    PubMed     Abstract available


    April 2019
  179. BELPERIO PS, Shahoumian TA, Loomis TP, Backus LI, et al
    Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Direct-Acting Antiviral Experienced Hepatitis C Patients.
    J Viral Hepat. 2019 Apr 22. doi: 10.1111/jvh.13115.
    PubMed     Abstract available


  180. DVORY-SOBOL H, Han B, Lu J, Yu M, et al
    In Vitro Resistance Profile of Hepatitis C Virus NS5A Inhibitor Velpatasvir in Genotypes 1 to 6.
    J Viral Hepat. 2019 Apr 22. doi: 10.1111/jvh.13116.
    PubMed     Abstract available


  181. BAJIS S, Grebely J, Cooper L, Smith J, et al
    Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112.
    PubMed     Abstract available


  182. INDOLFI G, Bailey H, Serranti D, Giaquinto C, et al
    Treatment and Monitoring of Children with Chronic Hepatitis C in the Pre-DAA Era: a European Survey of 38 Paediatric Specialists.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13111.
    PubMed     Abstract available


  183. KARNSAKUL W, Schwarz KB
    Management of HCV in Children in the Era of DAA's.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13113.
    PubMed     Abstract available


  184. POORDAD F, Sedghi S, Pockros PJ, Ravendhran N, et al
    Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13109.
    PubMed     Abstract available


  185. BACK D, Belperio P, Bondin M, Negro F, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.
    J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110.
    PubMed     Abstract available


  186. DI BISCEGLIE AM, King WC, Lisker-Melman M, Khalili M, et al
    Age, race and viral genotype are associated with the prevalence of Hepatitis B e antigen in children and adults with chronic Hepatitis B.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13104.
    PubMed     Abstract available


  187. TAMAKI N, Higuchi M, Kurosaki M, Kirino S, et al
    Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13103.
    PubMed     Abstract available


  188. CARABALLO CORTES K, Osuch S, Perlejewski K, Pawelczyk A, et al
    Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjec
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13108.
    PubMed     Abstract available


  189. WEI L, Pavlovic V, Bansal AT, Chen X, et al
    Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13107.
    PubMed     Abstract available


  190. WEN B, Zhang J, Liu W, Tang P, et al
    HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13106.
    PubMed     Abstract available


    March 2019
  191. HAGA H, Saito T, Okumoto K, Tomita K, et al
    Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus are equivalent between genotype B and C in long term.
    J Viral Hepat. 2019 Mar 28. doi: 10.1111/jvh.13099.
    PubMed     Abstract available


  192. DE LA TORRE A, Ahmad M, Ayoub F, Korogodsky M, et al
    Electronic Health Record Year and Country of Birth Testing and Patient Navigation to Increase Diagnosis of Chronic Viral Hepatitis.
    J Viral Hepat. 2019 Mar 28. doi: 10.1111/jvh.13098.
    PubMed     Abstract available


  193. SONNEVELD MJ, Van Oord GW, van Campenhout MJ, de Man RA, et al
    Relationship between hepatitis B Core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.
    J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13097.
    PubMed     Abstract available


  194. SIMMONS R, Ireland G, Ijaz S, Ramsay M, et al
    Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study.
    J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096.
    PubMed     Abstract available


  195. MAK LY, Seto WK, Hui RW, Fung J, et al
    Fibrosis evolution in chronic hepatitis B E-antigen negative patients across a 10-year interval.
    J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13095.
    PubMed     Abstract available


    February 2019
  196. WILSON EC, Turner C, Lin J, McFarland W, et al
    Hepatitis C seroprevalence and engagement in related care and treatment among transwomen.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13089.
    PubMed     Abstract available


  197. PLATT L, Stengel CM, Nkurunziza M, Muhangi D, et al
    Assessing risk of HIV and hepatitis C among people who inject drugs in East Africa: findings from a rapid assessment.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13088.
    PubMed     Abstract available


  198. MARTINEZ MG, Testoni B, Zoulim F
    Biological basis for functional cure of chronic hepatitis B.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13090.
    PubMed     Abstract available


  199. TURKOVA A, Volynets GV, Crichton S, Skvortsova TA, et al
    Advanced liver disease in Russian children and adolescents with chronic hepatitis C.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13093.
    PubMed     Abstract available


  200. DORE GJ
    HCV reinfection as a positive indication of high-risk population treatment access.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13092.
    PubMed     Abstract available


  201. LIM SG, Agcaoili J, De Souza NNA, Chan E, et al
    Therapeutic Vaccination for Chronic Hepatitis B: A Systematic Review and Meta-analysis.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13085.
    PubMed     Abstract available


  202. LATHAM NH, Pedrana A, Doyle JS, Howell J, et al
    Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13087.
    PubMed     Abstract available


  203. VANOPDORP JR, Ferrentino N, Strader DB, Lidofsky SD, et al
    Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13083.
    PubMed     Abstract available


  204. KARIMZADEH H, Usman Z, Frishman D, Roggendorf M, et al
    Genetic diversity of hepatitis D virus genotype 1 in Europe allows classification into subtypes.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13086.
    PubMed     Abstract available


  205. VAN HEES S, Chi H, Hansen B, Bourgeois S, et al
    Sustained off-treatment viral control is associated with high Hepatitis B Surface Antigen seroclearance rates in Caucasian patients with Nucleos(t)ide Analogue induced HBeAg seroconversion.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13084.
    PubMed     Abstract available


  206. LOMBARDI A, Rossotti R, Moioli MC, Merli M, et al
    The impact of HIV infection and MSM status on hepatitis A infection: the experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period.
    J Viral Hepat. 2019 Feb 22. doi: 10.1111/jvh.13082.
    PubMed     Abstract available


  207. IDILMAN R, Demir M, Aladag M, Erol C, et al
    Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
    J Viral Hepat. 2019 Feb 11. doi: 10.1111/jvh.13075.
    PubMed     Abstract available


  208. FERENCI P, Bourgeois S, Buggisch P, Norris S, et al
    Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observation
    J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080.
    PubMed     Abstract available


  209. GIADANS CG, Rios DA, Ameigeiras B, Pietrantonio AM, et al
    Chronic Hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13078.
    PubMed     Abstract available


  210. PALAZZO D, Biliotti E, Esvan R, Volpicelli L, et al
    Vitamin D deficiency and health-related quality of life in chronic hepatitis C.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076.
    PubMed     Abstract available


  211. LAWITZ E, Poordad F, Anderson LJ, Vesay M, et al
    Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079.
    PubMed     Abstract available


  212. SHYU YC, Huang TS, Chien CH, Yeh CT, et al
    Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: a population-based cohort study.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13077.
    PubMed     Abstract available


    January 2019
  213. BLADOWSKA J, Pawlowski T, Fleischer-Stepniewska K, Knysz B, et al
    Interferon-free Therapy as the Cause of White Matter Tracts and Cerebral Perfusion Recovery in Patients with Chronic Hepatitis C.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13069.
    PubMed     Abstract available


  214. KRANIDIOTI H, Manolakopoulos S, Kontos G, Breen MS, et al
    Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg negative chronic hepatitis B.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13068.
    PubMed     Abstract available


  215. JACK K, Thomson BJ, Irving WL
    Testing for hepatitis C virus infection in UK Prisons: what actually happens?
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13071.
    PubMed     Abstract available


  216. CHEN WC, Wei CK, Lee JC
    MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of heme oxygenase-1 expression.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13072.
    PubMed     Abstract available


  217. HARRIS RJ, Harris H, Mandal S, Ramsay M, et al
    Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
    J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13063.
    PubMed     Abstract available


  218. RUANE P, Strasser SI, Gane EJ, Hyland RH, et al
    Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study.
    J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13067.
    PubMed     Abstract available


  219. MAHALE P, Aka P, Chen X, Pfeiffer RM, et al
    Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia.
    J Viral Hepat. 2019 Jan 20. doi: 10.1111/jvh.13065.
    PubMed     Abstract available


  220. RIVERO-JUAREZ A, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, et al
    Hepatitis e virus in spanish donors and the necessity for screening.
    J Viral Hepat. 2019 Jan 19. doi: 10.1111/jvh.13064.
    PubMed     Abstract available


  221. GIROMETTI N, Devitt E, Phillips J, Nelson M, et al
    High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection.
    J Viral Hepat. 2019 Jan 19. doi: 10.1111/jvh.13066.
    PubMed     Abstract available


  222. NARAYANAN S, Abutaleb A, Sherman KE, Kottilil S, et al
    Clinical features and determinants of chronicity in hepatitis e virus infection.
    J Viral Hepat. 2019 Jan 12. doi: 10.1111/jvh.13059.
    PubMed     Abstract available


  223. XU R, Yu Y, Leitch ECM, Wang M, et al
    HCV genotype 6 prevalence, spontaneous clearance and diversity amongst elderly members of the Li ethnic minority in Baisha County, China.
    J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13062.
    PubMed     Abstract available


  224. KIM HS, Yang JD, El-Serag HB, Kanwal F, et al
    Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey.
    J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13060.
    PubMed     Abstract available


  225. KONG Y, Sun Y, Zhou J, Wu X, et al
    Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
    J Viral Hepat. 2019 Jan 9. doi: 10.1111/jvh.13058.
    PubMed     Abstract available


    December 2018
  226. ZHOU L, Li X, Huang X, Chen L, et al
    Soluble Programmed Death-1 Is a Useful Indicator for Inflammatory and Fibrosis Severity in Chronic Hepatitis B.
    J Viral Hepat. 2018 Dec 22. doi: 10.1111/jvh.13055.
    PubMed     Abstract available


  227. RODRIGO C, Leung P, Lloyd AR, Bull RA, et al
    Genomic variability of within-host hepatitis C variants in acute infection.
    J Viral Hepat. 2018 Dec 22. doi: 10.1111/jvh.13051.
    PubMed     Abstract available


  228. FONG TL, Lee BT, Tien A, Chang M, et al
    Improvement of Bone Mineral Density and Markers of Proximal Renal Tubular Function in Chronic Hepatitis B Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.
    J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13053.
    PubMed     Abstract available


  229. DI LELLO FA, Ridruejo E, Martinez AP, Perez PS, et al
    Molecular epidemiology of hepatitis b virus mutants associated with vaccine-escape, drug-resistance and diagnosis failure.
    J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13052.
    PubMed     Abstract available


  230. LOGGI E, Vukotic R, Conti F, Grandini E, et al
    Serum Hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative Chronic Hepatitis B.
    J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13054.
    PubMed     Abstract available


  231. RAMACHANDRAN J, Budd S, Slattery H, Muller K, et al
    Hepatitis C virus infection in Australian psychiatric in-patients: a multicenter study of seroprevalence, risk factors and treatment experience.
    J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13056.
    PubMed     Abstract available


  232. HENGST J, Klein AL, Lunemann S, Deterding K, et al
    Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.
    J Viral Hepat. 2018 Dec 8. doi: 10.1111/jvh.13050.
    PubMed     Abstract available


  233. MARCANTONIO C, Pezzotti P, Bruni R, Taliani G, et al
    Incidence of hepatitis E virus infection among blood donors in a high endemic area of Central Italy.
    J Viral Hepat. 2018 Dec 7. doi: 10.1111/jvh.13049.
    PubMed     Abstract available


  234. POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
    Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
    PubMed     Abstract available


  235. LEE SS, Kim CY, Kim BR, Cha RR, et al
    Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
    PubMed     Abstract available


  236. RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
    Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
    PubMed     Abstract available


    November 2018
  237. HOLMES JA, Carlton-Smith C, Kim AY, Dumas EO, et al
    Dynamic Changes in Innate Immune Responses During Direct Acting Antiviral Therapy for HCV Infection.
    J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13041.
    PubMed     Abstract available


  238. MIJOCEVIC H, Karimzadeh H, Seebach J, Usman Z, et al
    Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.
    J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13044.
    PubMed     Abstract available


  239. KAPILA N, Flocco G, Al Khalloufi K, Zervos XB, et al
    Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting anti-viral therapy without ribavirin.
    J Viral Hepat. 2018 Nov 18. doi: 10.1111/jvh.13042.
    PubMed     Abstract available


  240. BUTT ZA, Mak S, Gesink D, Gilbert M, et al
    Applying core theory and spatial analysis to identify Hepatitis C Virus infection 'core areas' in British Columbia, Canada.
    J Viral Hepat. 2018 Nov 17. doi: 10.1111/jvh.13043.
    PubMed     Abstract available


  241. SCHULKIND J, Stephens B, Ahmad F, Johnston L, et al
    High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
    J Viral Hepat. 2018 Nov 13. doi: 10.1111/jvh.13035.
    PubMed     Abstract available


  242. FLAMM S, Mutimer D, Asatryan A, Wang S, et al
    Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
    J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038.
    PubMed     Abstract available


  243. GILL US, Kennedy PTF
    The impact of currently licensed therapies on viral and immune responses in Chronic Hepatitis B: considerations for future novel therapeutics.
    J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13040.
    PubMed     Abstract available


  244. SONG J, Yang F, Wang S, Tikande S, et al
    Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis.
    J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13036.
    PubMed     Abstract available


  245. SERFATY L, Jacobson I, Rockstroh J, Altice FL, et al
    The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13037.
    PubMed     Abstract available


  246. YOUNG K, Liu B, Bhuket T, Gish RG, et al
    Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039.
    PubMed     Abstract available


  247. ORR C, Aartun J, Masur H, Kottilil S, et al
    Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2018 Nov 1. doi: 10.1111/jvh.13034.
    PubMed     Abstract available


  248. YOUNOSSI Z, Papatheodoridis G, Cacoub P, Negro F, et al
    The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.
    J Viral Hepat. 2018;25 Suppl 3:6-14.
    PubMed     Abstract available


    October 2018
  249. BRICHLER S, Nahon P, Zoulim F, Layese R, et al
    Non-virological factors are drivers of Hepatocellular Carcinoma in virosuppressed Hepatitis B cirrhosis: results of ANRS CO12 CirVir cohort.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13029.
    PubMed     Abstract available


  250. DONG XQ, Wu Z, Zhao H, Wang GQ, et al
    Evaluation and Comparison of Thirty Non-invasive Models for Diagnosing Liver Fibrosis in Chinese Hepatitis B Patients.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13031.
    PubMed     Abstract available


  251. WU DB, Jiang W, Wang YH, Chen B, et al
    Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real-world experience of a retrospective study.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13033.
    PubMed     Abstract available


  252. WU Z, Dong X, Wang G, Zhao H, et al
    Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13030.
    PubMed     Abstract available


  253. ABDEL GHAFFAR TY, Naghi SE, Gawad MA, Helmy S, et al
    Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13032.
    PubMed     Abstract available


  254. HUANG J, Yin P, Zhang L
    COPII cargo claudin-12 promotes hepatitis C virus entry.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13026.
    PubMed     Abstract available


  255. SARKAR M, Lai JC, Sawinski D, Zeigler TE, et al
    Sex Hormone Levels by Presence and Severity of Cirrhosis in Women With Chronic Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027.
    PubMed     Abstract available


  256. CHEVALIEZ S, Rodriguez C, Poiteau L, Soulier A, et al
    Primary Resistance of Hepatitis B Virus to Nucleoside and Nucleotide Analogues.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13025.
    PubMed     Abstract available


  257. WANG M, Ping Y, Li Z, Li J, et al
    Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signaling.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13024.
    PubMed     Abstract available


  258. VAZIRI A, Gimson A, Agarwal K, Aldersley M, et al
    Liver transplant listing for hepatitis C associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13022.
    PubMed     Abstract available


  259. GIRARDIN F, Hearmon N, Negro F, Eddowes L, et al
    Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost-Effectiveness Analysis.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13023.
    PubMed     Abstract available


  260. KNOP V, Hofmann WP, Buggisch P, Klinker H, et al
    Estimation of liver fibrosis by non-commercial serum markers in comparison to transient elastography in patients with chronic hepatitis C virus infection receiving direct acting antiviral treatment.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13021.
    PubMed     Abstract available


  261. MOREY S, Hamoodi A, Jones D, Young T, et al
    Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017.
    PubMed     Abstract available


  262. GOUTZAMANIS S, Doyle J, Higgs P, Hellard M, et al
    Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13020.
    PubMed     Abstract available


  263. ASGARI S, Chaturvedi N, Scepanovic P, Hammer C, et al
    Human genomics of acute liver failure due to hepatitis B virus infection: an exome sequencing study in liver transplant recipients.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13019.
    PubMed     Abstract available


  264. MCLEOD A, Weir A, Hutchinson SJ, Goldberg DJ, et al
    Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13016.
    PubMed     Abstract available


  265. JAYASUNDARA D, Hui BB, Regan DG, Heywood AE, et al
    Modelling the decline and future of hepatitis A transmission in Australia.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13018.
    PubMed     Abstract available


    September 2018
  266. OU G, Liu X, Yang L, Yu H, et al
    Relationship between HLA-DPA1 mRNA expression and susceptibility to hepatitis B.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13012.
    PubMed     Abstract available


  267. JOO EJ, Chang Y, Yeom JS, Cho YK, et al
    Chronic Hepatitis B Virus Infection and Risk of Dyslipidemia: A Cohort Study.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13014.
    PubMed     Abstract available


  268. KWON JA, Dore GJ, Grebely J, Hajarizadeh B, et al
    Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modeling study.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13013.
    PubMed     Abstract available


  269. HERNANDEZ-CONDE M, Fernandez I, Perello C, Gallego A, et al
    Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort.
    J Viral Hepat. 2018 Sep 28. doi: 10.1111/jvh.13008.
    PubMed     Abstract available


  270. MALAGUTI A, Sani F, Stephens BP, Ahmad F, et al
    Change in injecting behaviour among people treated for hepatitis C virus: the role of intimate partnerships.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13009.
    PubMed     Abstract available


  271. XIA Y, Pan W, Ke X, Skibbe K, et al
    Differential escape of HCV from CD8(+) T cell selection pressure between China and Germany depends on the presenting HLA class I molecule.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13011.
    PubMed     Abstract available


  272. MIAO Z, Zhang S, Ma Z, Hakim MS, et al
    Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13010.
    PubMed     Abstract available


  273. LIU Z, Chen X, Zhang T
    Reply to "The epidemiology of hepatitis B virus infection in China".
    J Viral Hepat. 2018 Sep 21. doi: 10.1111/jvh.13007.
    PubMed     Abstract available


  274. MACIAS J, Tellez F, Rivero-Juarez A, Palacios R, et al
    Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13003.
    PubMed     Abstract available


  275. LIN SYC, Magalis BR, Salemi M, Liu HF, et al
    Origin and Dissemination of Hepatitis B Virus Genotype C in East Asia Revealed by Phylodynamic Analysis and Historical Correlates.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13006.
    PubMed     Abstract available


  276. ZHAO H
    The epidemiology of hepatitis B virus infection in China.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13004.
    PubMed     Abstract available


  277. IWAMOTO M, Calzia A, Dublineau A, Rouet F, et al
    Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a Genotype 1 and 6 predominant patient population in Cambodia.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13002.
    PubMed     Abstract available


  278. BIANCHI FP, Gallone MS, Gallone MF, Larocca AMV, et al
    HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: an Italian study among medical students.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13001.
    PubMed     Abstract available


  279. RODGERS MA, Holzmayer V, Vallari A, Olivo A, et al
    Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12996.
    PubMed     Abstract available


  280. DUONG MC, McLaws ML
    Screening hemodialysis patients for hepatitis C in Vietnam: the inconsistency between common hepatitis C virus serological and virological tests.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12994.
    PubMed     Abstract available


  281. VAN CAMPENHOUT MJH, Brouwer WP, Xie Q, Guo S, et al
    Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg positive chronic hepatitis B infection: ARES long-term follow-up.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12997.
    PubMed     Abstract available


  282. SUKRITI S, Choudhary MC, Maras JS, Sharma S, et al
    Extracellular Vesicles From Hepatitis B Patients Serve As Reservoir Of Hepatitis B Virus DNA.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12995.
    PubMed     Abstract available


  283. VROLING H, Oordt-Speets AM, Madeddu G, Babudieri S, et al
    A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12998.
    PubMed     Abstract available


  284. CHAN HLY, Chan FWS, Hui AJ, Li MKK, et al
    Switching to Peginterferon for Chronic Hepatitis B Patients with Hepatitis B e Antigen Seroconversion on Entecavir - A Prospective Study.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.13000.
    PubMed     Abstract available


  285. HONER ZU SIEDERDISSEN C, Maasoumy B, Cornberg M
    New viral biomarkers for Hepatitis B: Are we able to change practice?
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12993.
    PubMed     Abstract available


  286. LAMPERTICO P, Brunetto MR, Craxi A, Gaeta GB, et al
    Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12999.
    PubMed     Abstract available


  287. SHEN J, Liu J, Li C, Wen T, et al
    The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis.
    J Viral Hepat. 2018;25:1057-1065.
    PubMed     Abstract available


  288. WANG J, Yu Y, Li G, Shen C, et al
    Natural history of serum HBV-RNA in chronic HBV infection.
    J Viral Hepat. 2018;25:1038-1047.
    PubMed     Abstract available


    August 2018
  289. LAFFERTY L, Rance J, Grebely J, Lloyd AR, et al
    Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12987.
    PubMed     Abstract available


  290. PERPINAN E, Caro-Perez N, Garcia-Gonzalez N, Gregori J, et al
    Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12986.
    PubMed     Abstract available


  291. SAEED S, Moodie EE, Strumpf E, Gill J, et al
    Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in HIV/Hepatitis C Co-Infected Individuals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12985.
    PubMed     Abstract available


  292. JONES H, Patel P, Sears D
    Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988.
    PubMed     Abstract available


  293. MACIAS J, Granados R, Tellez F, Merino D, et al
    Similar recovery of liver function after response to all oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12990.
    PubMed     Abstract available


  294. LIM SG, Phyo WW, Shah SR, Win KM, et al
    Findings from a large asian chronic hepatitis c real life study.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
    PubMed     Abstract available


  295. GROC S, Abbate JL, Le Gal F, Gerber A, et al
    High Prevalence and Diversity of Hepatitis B and Hepatitis Delta Virus in Gabon.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12991.
    PubMed     Abstract available


  296. DIRKS M, Haag K, Pflugrad H, Tryc AB, et al
    Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
    J Viral Hepat. 2018 Aug 18. doi: 10.1111/jvh.12979.
    PubMed     Abstract available


  297. SINGH A, Kumari S, Kumar P, De A, et al
    Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus (HCV) Infection with Severe Renal Insufficiency.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12983.
    PubMed     Abstract available


  298. ARYA RP, Mishra N, Biswas K, Arankalle VA, et al
    Association of Toll-like receptor 4 polymorphism with Hepatitis E virus infected Indian patients.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12980.
    PubMed     Abstract available


  299. MASETTI C, Lionetti R, Lupo M, Siciliano M, et al
    Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982.
    PubMed     Abstract available


  300. WANG S, Wang J, Fan MJ, Li TY, et al
    Identified OAS3 gene variants associated with coexistence of HBsAg and anti-HBs in chronic HBV infection.
    J Viral Hepat. 2018;25:904-910.
    PubMed     Abstract available


  301. CHOI YH, Zhang X, Tran C, Skinner B, et al
    Expression profiles of host immune response-related genes against HEV genotype 3 and genotype 1 infections in rhesus macaques.
    J Viral Hepat. 2018;25:986-995.
    PubMed     Abstract available


  302. WANG B, Carey I, Bruce M, Montague S, et al
    HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    J Viral Hepat. 2018;25:886-893.
    PubMed     Abstract available


    July 2018
  303. SCOTT N, Sacks-Davis R, Pedrana A, Doyle J, et al
    Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975.
    PubMed     Abstract available


  304. PINTILIE H, Brook G
    Commentary: A review of risk of hepatitis B and C transmission through biting or spitting.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12976.
    PubMed     Abstract available


  305. DARVISHIAN M, Janjua NZ, Chong M, Cook D, et al
    Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12977.
    PubMed     Abstract available


  306. BILOUNGA NDONGO C, Eteki L, Siedner M, Mbaye R, et al
    Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12974.
    PubMed     Abstract available


  307. SUGIURA A, Joshita S, Umemura T, Yamazaki T, et al
    Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
    J Viral Hepat. 2018 Jul 25. doi: 10.1111/jvh.12973.
    PubMed     Abstract available


  308. WEI L, Chen D, Zhang B, Zhao Y, et al
    Long-term Outcome and Recurrence of Hepatitis B Virus following Liver Transplantation from Hepatitis B Surface Antigen-positive Donors in a Chinese Population.
    J Viral Hepat. 2018 Jul 15. doi: 10.1111/jvh.12972.
    PubMed     Abstract available


  309. KIM BG, Park NH, Lee SB, Lee H, et al
    Mortality, liver transplantation, and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12971.
    PubMed     Abstract available


  310. NOMURA M, Tsuge M, Uchida T, Hiraga N, et al
    CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.
    PubMed     Abstract available


  311. KABERG M, Naver G, Hammarberg A, Weiland O, et al
    Incidence and spontaneous clearance of hepatitis C (HCV) in PWID at the Stockholm Needle Exchange - importance for HCV elimination.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12969.
    PubMed     Abstract available


  312. HAYASHI K, Ishigami M, Ishizu Y, Kuzuya T, et al
    Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12967.
    PubMed     Abstract available


  313. YUE X, Yang T, Zhao Y
    Response to letter to the editor: Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?!
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12968.
    PubMed     Abstract available


  314. YOUNOSSI ZM, Stepanova M, Henry L, Han KH, et al
    Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jul 4. doi: 10.1111/jvh.12965.
    PubMed     Abstract available


  315. MOHAMED Z, Rwegasha J, Kim JU, Shimakawa Y, et al
    The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12966.
    PubMed     Abstract available


  316. LIU Y, Song C, Ni H, Jiao W, et al
    UBE2L3, a susceptibility gene that plays oncogenic role in hepatitis B related hepatocellular carcinoma.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12963.
    PubMed     Abstract available


  317. ANWAR N, Sherman KE
    Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical?
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12962.
    PubMed     Abstract available


  318. TAN J, Mao X, Zhang G, Wang W, et al
    Hepatitis B surface antigen positivity during pregnancy and risk of gestational diabetes mellitus: A systematic review and meta-analysis.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12964.
    PubMed     Abstract available


    June 2018
  319. HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
    Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
    PubMed     Abstract available


  320. KUMAR R
    Hepatitis B Virus Infection and Diabetes Mellitus: An Adverse Relationship.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12949.
    PubMed     Abstract available


  321. ZHOU TC, Li X, Chen LJ, Fan JH, et al
    Differential expression profile of hepatic circular RNAs in chronic hepatitis B.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12944.
    PubMed     Abstract available


  322. LUTTERKORT GL, Wranke A, Hengst J, Yurdaydin C, et al
    Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12947.
    PubMed     Abstract available


  323. HARIDY J, Wigg A, Muller K, Ramachandran J, et al
    Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
    PubMed     Abstract available


  324. DINESHA TR, Boobalan J, Sivamalar S, Subashini D, et al
    Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.
    J Viral Hepat. 2018;25:718-723.
    PubMed     Abstract available


    May 2018
  325. LIU Z, Yang Q, Shi O, Ye W, et al
    The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
    PubMed     Abstract available


  326. KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
    Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
    PubMed     Abstract available


  327. AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
    Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
    PubMed     Abstract available


  328. MARCO A, Roget M, Cervantes M, Forne M, et al
    Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
    PubMed     Abstract available


  329. ZHOU Y, Zhou YH
    Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12941.
    PubMed     Abstract available


  330. AGARWAL K, Ahn SH, Elkhashab M, Lau AH, et al
    Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12942.
    PubMed     Abstract available


  331. JACKSON C, Gunson RN, Bradley-Stewart A, Bennet S, et al
    Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12939.
    PubMed     Abstract available


  332. FUJITA M, Sugiyama M, Sato Y, Nagashima K, et al
    Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12933.
    PubMed     Abstract available


  333. JEONG Y, Jin B, Lee HW, Park HJ, et al
    Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
    PubMed     Abstract available


  334. AKRAM A, Islam SMR, Munshi SU, Tabassum S, et al
    Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12931.
    PubMed     Abstract available


  335. CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
    Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
    PubMed     Abstract available


  336. DEMING R, Ford MM, Moore MS, Lim S, et al
    Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
    J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
    PubMed     Abstract available


  337. CHENG CY, Wu HH, Zou H, Lo YC, et al
    Epidemiological characteristics and associated factors of acute hepatitis A outbreak among HIV-coinfected men who have sex with men in Taiwan, June 2015-December 2016.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12926.
    PubMed     Abstract available


  338. CHO YY, Lee JH, Chang Y, Nam JY, et al
    Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12927.
    PubMed     Abstract available


  339. ZHOU TC, Lai X, Feng MH, Tang Y, et al
    Systematic review and meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12928.
    PubMed     Abstract available


  340. WANG J, Xia J, Zhang R, Yan X, et al
    A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12925.
    PubMed     Abstract available


    April 2018
  341. CHI H, Japhary A, de Man RA, de Knegt RJ, et al
    Younger Age and Language Barriers are Associated with Non-adherence to Clinical Follow-up in Hepatitis B Treatment.
    J Viral Hepat. 2018 Apr 21. doi: 10.1111/jvh.12920.
    PubMed     Abstract available


  342. MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
    Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
    PubMed     Abstract available


  343. NFOR ON, Wu MF, Debnath T, Lee CT, et al
    Hepatitis B virus infection in Taiwan: The role of NTCP rs2296651 variant in relation to sex.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12912.
    PubMed     Abstract available


  344. BOYD A, Moh R, Maylin S, Chekaraou MA, et al
    Precore G1896A mutation is associated with reduced rates of HBsAg-seroclearance in treated HIV-hepatitis B virus co-infected patients from Western Africa.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12914.
    PubMed     Abstract available


  345. WADE AJ, McCormack A, Roder C, McDonald K, et al
    Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
    PubMed     Abstract available


  346. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
    PubMed     Abstract available


  347. CAREY I, Byrne R, Childs K, Horner M, et al
    Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12916.
    PubMed     Abstract available


  348. GENCAY M, Seffner A, Pabinger S, Gautier J, et al
    Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12915.
    PubMed     Abstract available


  349. ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
    Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
    PubMed     Abstract available


  350. YOO SH, Kwon JH, Nam SW, Kim HY, et al
    Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
    PubMed     Abstract available


  351. KOC OM, Savelkoul PHM, van Loo IHM, Peeters A, et al
    Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naive and non-responding adults.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12909.
    PubMed     Abstract available


  352. KUANG XJ, Jia RR, Huo RR, Yu JJ, et al
    Systematic review of risk factors of hepatocellular carcinoma after Hepatitis B Surface Antigen seroclearance.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12905.
    PubMed     Abstract available


  353. SRIDHAR S
    Use of S17 fragment containing hepatitis E virus infectious clones in cell culture experiments: the fine print does matter.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12902.
    PubMed     Abstract available


  354. TANG X, Allain JP, Wang H, Rong X, et al
    Incidence of HBV infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12901.
    PubMed     Abstract available


  355. WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
    Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
    PubMed     Abstract available


  356. SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
    Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
    PubMed     Abstract available


  357. MOORE MS, Bocour A, Winters A
    Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
    PubMed     Abstract available


  358. PENG Z, Hong-Bo D, Guang-Dong T, Xiao-Ke L, et al
    Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: a multicentre perspective in China.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12903.
    PubMed     Abstract available


  359. YUE X, Ge C, Zhuge S, He H, et al
    Changes and analysis of anti-HBs titres after primary immunization in 1- to 16-year-old Chinese children: A hospital-based study.
    J Viral Hepat. 2018;25:373-380.
    PubMed     Abstract available


    March 2018
  360. GODOY P, Carmona G, Manzanares S, Jane M, et al
    Trends and risk factors of hepatitis A in Catalonia after the introduction of a hepatitis A+B vaccination program.
    J Viral Hepat. 2018 Mar 31. doi: 10.1111/jvh.12900.
    PubMed     Abstract available


  361. RICCO G, Popa DC, Cavallone D, Iacob S, et al
    Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12895.
    PubMed     Abstract available


  362. HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
    Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
    PubMed     Abstract available


  363. WANG H, Swann R, Thomas E, Innes HA, et al
    Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
    PubMed     Abstract available


  364. BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
    HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
    PubMed     Abstract available


  365. NJOUOM R, Siffert I, Texier G, Lachenal G, et al
    The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
    PubMed     Abstract available


  366. GOOSSENS N, de Vito C, Mangia A, Clement S, et al
    Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
    PubMed     Abstract available


  367. LI M, Gan Y, Fan C, Yuan H, et al
    Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12892.
    PubMed     Abstract available


  368. FEDELI U
    Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
    PubMed     Abstract available


  369. PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
    Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    J Viral Hepat. 2018;25 Suppl 1:6-17.
    PubMed     Abstract available


  370. XIANG-CHUN D, Xiao-Qing Y, Ting-Ting Y, Zhen-Hui L, et al
    Alpha-enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathway.
    J Viral Hepat. 2018;25:289-295.
    PubMed     Abstract available


    February 2018
  371. DUARTE G, Williams CJ, Vasconcelos P, Nogueira P, et al
    Capacity to report on mortality attributable to chronic Hepatitis B and C infections by Member States: an exercise to monitor progress toward viral hepatitis elimination.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12882.
    PubMed     Abstract available


  372. MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
    Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
    PubMed     Abstract available


  373. CHEN JY, Ren Y, Yan P, Belina ME, et al
    Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
    PubMed     Abstract available


  374. LI J, Zhang T, Gordon SC, Rupp LB, et al
    Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
    PubMed     Abstract available


  375. YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
    Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
    PubMed     Abstract available


  376. OLVEIRA A, Dominguez L, Troya J, Arias A, et al
    Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
    PubMed     Abstract available


  377. CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
    PubMed     Abstract available


  378. LEE WC, Chou HS, Lee CS, Wu TH, et al
    Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation.
    J Viral Hepat. 2018 Feb 12. doi: 10.1111/jvh.12880.
    PubMed     Abstract available


  379. CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
    The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
    PubMed     Abstract available


  380. HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
    PubMed     Abstract available


  381. DELFINO CM, Cerrudo CS, Biglione M, Oubina JR, et al
    A comprehensive bioinformatic analysis of hepatitis D virus (HDV) full-length genomes.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12876.
    PubMed     Abstract available


  382. ZHONG GC, Wu YL, Hao FB, Rao XW, et al
    Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12878.
    PubMed     Abstract available


  383. ZAKARIA HM, Salem TA, El-Araby HA, Salama RM, et al
    Steroid therapy in children with fulminant hepatitis A.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12873.
    PubMed     Abstract available


  384. PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
    Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
    PubMed     Abstract available


  385. LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
    Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
    PubMed     Abstract available


  386. WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
    PubMed     Abstract available


    January 2018
  387. ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
    Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
    PubMed     Abstract available


  388. GUPTA S, Rout G, Patel AH, Mahanta M, et al
    Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
    PubMed     Abstract available


  389. FABER M, Willrich N, Schemmerer M, Rauh C, et al
    Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12868.
    PubMed     Abstract available


  390. HARRIS M, Bonnington O, Harrison G, Hickman M, et al
    Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
    J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
    PubMed     Abstract available


  391. YANG C, Yu W, Bi Y, Long F, et al
    Increased estradiol in hepatitis E virus infected pregnant women promote viral replication.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12865.
    PubMed     Abstract available


  392. ZHOU PP, Xu J, Dai MJ, Shi YY, et al
    The immunosuppressive effects of CD4(+) CD25(+) regulatory T cells on dendritic cells in patients with chronic hepatitis B.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12863.
    PubMed     Abstract available


  393. AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
    Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
    PubMed     Abstract available


  394. AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
    Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
    PubMed     Abstract available


  395. COLOMBO M, Boccaccio V
    Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
    PubMed     Abstract available


  396. CHO H, Ahn H, Lee DH, Lee JH, et al
    Entecavir and Tenofovir Reduce Hepatitis B Virus-related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12855.
    PubMed     Abstract available


  397. LAU KC, Osiowy C, Giles E, Lusina B, et al
    Deep Sequencing Shows Low Level Oncogenic Hepatitis B Virus Variants Persisting Post-Liver Transplant Despite Potent Anti-HBV Prophylaxis.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12860.
    PubMed     Abstract available


  398. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
    Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
    PubMed     Abstract available


  399. YOUNG K, Haq K, MacLean S, Dudani R, et al
    Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
    PubMed     Abstract available


  400. FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
    Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
    PubMed     Abstract available


  401. SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
    Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
    J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
    PubMed     Abstract available


    December 2017
  402. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    PubMed     Abstract available


  403. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    PubMed     Abstract available


  404. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    PubMed     Abstract available


  405. CHEN CH, Hsu YC, Lu SN, Hung CH, et al
    The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12851.
    PubMed     Abstract available


  406. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    PubMed     Abstract available


  407. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    PubMed     Abstract available


  408. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    PubMed     Abstract available


  409. ZENG QL, Xu GH, Wang B, Li ZQ, et al
    Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12848.
    PubMed     Abstract available


  410. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    PubMed     Abstract available


  411. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    PubMed     Abstract available


  412. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    PubMed     Abstract available


  413. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    PubMed     Abstract available


  414. LIU DP, Lu W, Zhang ZQ, Wang YB, et al
    Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
    J Viral Hepat. 2017 Dec 12. doi: 10.1111/jvh.12842.
    PubMed     Abstract available


  415. FERREIRA GLC, Marano C, De Moerlooze L, Guignard A, et al
    Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: a population-based cohort study using the UK Clinical Practice Research Datalink.
    J Viral Hepat. 2017 Dec 8. doi: 10.1111/jvh.12841.
    PubMed     Abstract available


  416. NAM JY, Chang Y, Cho H, Kang SH, et al
    Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    J Viral Hepat. 2017 Dec 1. doi: 10.1111/jvh.12838.
    PubMed     Abstract available


    November 2017
  417. CHEN Y, Xie C, Zhang Y, Li Y, et al
    Knowledge regarding Hepatitis B Mother-to-child Transmission among Healthcare Workers in South China.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12839.
    PubMed     Abstract available


  418. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
    PubMed     Abstract available


  419. TAMORI A, Abiru S, Enomoto H, Kioka K, et al
    Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
    PubMed     Abstract available


  420. CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
    IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
    PubMed     Abstract available


  421. WANG Y, Liang X, Yang J, Wang H, et al
    Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12835.
    PubMed     Abstract available


  422. LIU J, Zhang S, Liu M, Wang Q, et al
    Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: a population-based cross-sectional study.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12829.
    PubMed     Abstract available


  423. LEE HR, Cho YY, Lee GY, You DG, et al
    A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12831.
    PubMed     Abstract available


  424. YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
    Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
    PubMed     Abstract available


  425. JENG WJ, Chen YC, Liaw YF
    Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12833.
    PubMed     Abstract available


  426. TANAKA J, Akita T, Ohisa M, Sakamune K, et al
    Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
    PubMed     Abstract available


  427. HU Y, Xu C, Xu B, Hu L, et al
    Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12834.
    PubMed     Abstract available


  428. HSU YC, Ho HJ, Lee TY, Huang YT, et al
    Temporal Trend and Risk Determinants of Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Entecavir or Tenofovir.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12832.
    PubMed     Abstract available


  429. KEISER O, Giudici F, Mullhaupt B, Junker C, et al
    Trends in hepatitis C-related mortality in Switzerland.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
    PubMed     Abstract available


  430. BROWN A, Hezode C, Zuckerman E, Foster GR, et al
    Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
    PubMed     Abstract available


  431. DUCHESNE L, Lacombe K
    Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.
    J Viral Hepat. 2017 Nov 13. doi: 10.1111/jvh.12827.
    PubMed     Abstract available


  432. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    PubMed     Abstract available


  433. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    PubMed     Abstract available


  434. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    PubMed     Abstract available


  435. CANNIZZO ES, Tincati C, Binda F, Ronzi P, et al
    Unconventional T-cells in Chronic Hepatitis B Patients on Long-Term Suppressive Therapy with Tenofovir followed by a Peg-IFN Add-On Strategy: a randomized study.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12820.
    PubMed     Abstract available


  436. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    PubMed     Abstract available


  437. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    PubMed     Abstract available


  438. FOSTER G
    Editorial for "Supplement on Optimal Therapy for Chronic Hepatitis B in China".
    J Viral Hepat. 2017;24 Suppl 1:3.
    PubMed    


  439. LIU J, Chen T, Zhao Y
    Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
    J Viral Hepat. 2017;24 Suppl 1:6-11.
    PubMed     Abstract available


  440. PAN HY, Pan HY, Song WY, Zheng W, et al
    Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    J Viral Hepat. 2017;24 Suppl 1:29-35.
    PubMed     Abstract available


  441. LUO XD, Chen XF, Zhou Y, Chen XP, et al
    Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNalpha-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    J Viral Hepat. 2017;24 Suppl 1:36-42.
    PubMed     Abstract available


  442. YI W, Li MH, Xie Y, Wu J, et al
    Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2017;24 Suppl 1:49-56.
    PubMed     Abstract available


  443. LI SY, Li H, Xiong YL, Liu F, et al
    Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.
    J Viral Hepat. 2017;24 Suppl 1:12-20.
    PubMed     Abstract available


  444. HUANG D, Sansas B, Jiang JH, Gong QM, et al
    Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
    J Viral Hepat. 2017;24 Suppl 1:66-74.
    PubMed     Abstract available


  445. SHANG J, Wen Q, Wang CC, Liu K, et al
    Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
    J Viral Hepat. 2017;24 Suppl 1:43-48.
    PubMed     Abstract available


  446. WANG ML, Chen EQ, Zhang DM, Du LY, et al
    Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    J Viral Hepat. 2017;24 Suppl 1:21-28.
    PubMed     Abstract available


  447. REN H
    The experience of management of chronic hepatitis B in China.
    J Viral Hepat. 2017;24 Suppl 1:4-5.
    PubMed     Abstract available


    October 2017
  448. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    PubMed     Abstract available


  449. LIANG X, Xie Q, Tan D, Ning Q, et al
    Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12814.
    PubMed     Abstract available


  450. MA N, Zhang X, Yang L, Zhou J, et al
    Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12817.
    PubMed     Abstract available


  451. CHOI HY, Kim Y, Cho H, Kim BH, et al
    Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
    PubMed     Abstract available


  452. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    PubMed     Abstract available


  453. OW MM, Hegazy D, Warshow UM, Cramp ME, et al
    Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
    J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
    PubMed     Abstract available


  454. SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
    Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
    PubMed     Abstract available


  455. YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
    Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
    PubMed     Abstract available


  456. NAYLOR PH, Mutchnick MG
    Immunotherapy for Hepatitis B in the Direct Acting Anti-viral Era: Reevaluating the Thymosin alpha1 Efficacy Trials in Light of a Combination Therapy Approach.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12807.
    PubMed     Abstract available


  457. WEN X, Su H, Wang Y, Pu Z, et al
    Prevalence and natural course of occult hepatitis B virus infection in residents of two communities of Wuwei City, Gansu Province, China.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12805.
    PubMed     Abstract available


  458. WONG NS, Lee CK, Ng SC, Wong HK, et al
    Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
    PubMed     Abstract available


  459. MARRONE A, Capoluongo N, D'Amore C, Pisaturo M, et al
    Eighteen-month-lamivudine-prophylaxis on preventing occult hepatitis b virus (hbv) infection reactivation in patients with hematologic malignancies receiving immunosuppression therapy.
    J Viral Hepat. 2017 Oct 13. doi: 10.1111/jvh.12802.
    PubMed     Abstract available


  460. CAMUS G, Han B, Asselah T, Hsieh D, et al
    Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
    PubMed     Abstract available


  461. TANG L, Parker A, Flores Y, Dellario M, et al
    Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
    PubMed     Abstract available


  462. NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
    Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
    PubMed     Abstract available


  463. SRIDHAR S, Chan JFW, Yap DYH, Teng JLL, et al
    Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12799.
    PubMed     Abstract available


  464. WEIL C, Mehta D, Koren G, Pinsky B, et al
    Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
    PubMed     Abstract available


  465. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    PubMed     Abstract available


  466. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    PubMed     Abstract available


  467. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    PubMed     Abstract available


  468. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    PubMed     Abstract available


    August 2017
  469. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    PubMed     Abstract available


  470. ZHENG H, Cui FQ, Wang FZ, Huang LF, et al
    The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.
    J Viral Hepat. 2017 Aug 23. doi: 10.1111/jvh.12757.
    PubMed     Abstract available


  471. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    PubMed     Abstract available


  472. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    PubMed     Abstract available


  473. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    PubMed     Abstract available


  474. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    PubMed     Abstract available


  475. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    PubMed     Abstract available


  476. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    PubMed     Abstract available


  477. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    PubMed     Abstract available


  478. HUI RW, Seto WK, Cheung KS, Mak LY, et al
    Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case control study.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12766.
    PubMed     Abstract available


    July 2017
  479. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    PubMed     Abstract available


  480. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Abstract available


  481. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Abstract available


  482. CHAKRABARTY G, Bruce M, Horner M, Wang B, et al
    Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    J Viral Hepat. 2017 Jul 14. doi: 10.1111/jvh.12756.
    PubMed     Abstract available


  483. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    PubMed     Abstract available


  484. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    PubMed     Abstract available


  485. AL-QAHTANI AA, Al-Anazi MR, Nazir N, Wani K, et al
    Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12749.
    PubMed     Abstract available


  486. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    PubMed     Abstract available


  487. LI Q, Lu C, Li W, Huang Y, et al
    The gamma-glutamyl transpeptidase to albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12751.
    PubMed     Abstract available


    June 2017
  488. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    PubMed     Abstract available


  489. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    PubMed     Abstract available


  490. SIDDIQUI ZI, Farooqui SR, Azam SA, Afroz M, et al
    A comparative study of hepatitis B virus X protein mutants K130M, V131I and KV130/131MI to investigate their roles in fibrosis, cirrhosis and hepatocellular carcinoma.
    J Viral Hepat. 2017 Jun 27. doi: 10.1111/jvh.12747.
    PubMed     Abstract available


  491. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    PubMed     Abstract available


  492. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    PubMed     Abstract available


  493. DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
    Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
    PubMed     Abstract available


  494. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    PubMed     Abstract available


  495. YANG R, Gui X, Xiong Y, Gao S, et al
    Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
    PubMed     Abstract available


  496. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    PubMed     Abstract available


  497. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    PubMed     Abstract available


  498. STELMA F, van der Ree MH, Jansen L, Peters MW, et al
    HBsAg loss after peginterferon and nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12738.
    PubMed     Abstract available


  499. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    PubMed     Abstract available


  500. WONG RJ, Nguyen MT, Trinh HN, Chan C, et al
    Hepatitis B Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients: A Community-Based Real World Study.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12736.
    PubMed     Abstract available


  501. KIM HS, Rotundo L, Yang JD, Kim D, et al
    Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12735.
    PubMed     Abstract available


  502. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    PubMed     Abstract available


  503. NING L, Lin W, Hu X, Rong F, et al
    Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12733.
    PubMed     Abstract available


  504. LOK AS, Ganova-Raeva L, Cloonan Y, Punkova L, et al
    Prevalence of Hepatitis B Antiviral Drug Resistance Variants in North American Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12732.
    PubMed     Abstract available


  505. SHARMA S, Kumar A, Kar P, Agarwal S, et al
    Risk factors for vertical transmssion of hepatitis E virus infection.
    J Viral Hepat. 2017 Jun 1. doi: 10.1111/jvh.12730.
    PubMed     Abstract available


  506. HAN GR, Jiang HX, Wang CM, Ding Y, et al
    Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
    J Viral Hepat. 2017;24:514-521.
    PubMed     Abstract available


    May 2017
  507. BROUWER WP, van der Meer AJ, Boonstra A, Plompen EPC, et al
    Prediction of long-term clinical outcome in a diverse chronic hepatitis b population: role of the PAGE-B score.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12727.
    PubMed     Abstract available


  508. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    PubMed     Abstract available


  509. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    PubMed     Abstract available


  510. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    PubMed     Abstract available


  511. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    PubMed     Abstract available


  512. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    PubMed     Abstract available


  513. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    PubMed     Abstract available


  514. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    PubMed     Abstract available


  515. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    PubMed     Abstract available


  516. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    PubMed     Abstract available


    April 2017
  517. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    PubMed     Abstract available


  518. LAARIBI AB, Bortolotti D, Hannachi N, Mehri A, et al
    Increased levels of soluble HLA-G molecules in Tunisian patients with chronic hepatitis B infection.
    J Viral Hepat. 2017 Apr 21. doi: 10.1111/jvh.12718.
    PubMed     Abstract available


  519. CAI YJ, Dong JJ, Wang XD, Huang SS, et al
    A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12715.
    PubMed     Abstract available


  520. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    PubMed     Abstract available


  521. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    PubMed     Abstract available


  522. MGAIETH S, Kemp W, Gow P, Fink M, et al
    Impact of viral hepatitis etiology on survival outcomes in hepatocellular carcinoma: a large multi-center cohort study.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12717.
    PubMed     Abstract available


  523. HUANG CE, Yang YH, Chen YY, Chang JJ, et al
    The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma.
    J Viral Hepat. 2017 Apr 4. doi: 10.1111/jvh.12713.
    PubMed     Abstract available


    March 2017
  524. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    PubMed     Abstract available


  525. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    PubMed     Abstract available


  526. XU JH, Wang S, Xu ZN, Yu YY, et al
    Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12710.
    PubMed     Abstract available


  527. SU H, Shao Z, Pu Z, Wang Y, et al
    Overt and occult hepatitis B virus infection among community children in Northwest China.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12709.
    PubMed     Abstract available


  528. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    PubMed     Abstract available


    January 2017
  529. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    PubMed     Abstract available


  530. LI X, Gou C, Yao L, Lei Z, et al
    Patients with HBV-related acute-on-chronic liver failure have increased concentrations of extracellular histones aggravating cellular damage and systemic inflammation.
    J Viral Hepat. 2017;24:59-67.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: